MedTrace Logo

Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers

NCT04246749 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-01-29

No results posted yet for this study

Summary

A phase 1 healthy volunteer study to assess the mass balance, elimination, and metabolic profile of CRN00808. The study will be conducted in 2 parts: Part A, to characterize the absorption, distribution, metabolism, excretion, and mass balance of orally administered radio-labeled CRN00808; Part B, to determine the absolute bioavailability of CRN00808 administered using CRN00808 and radio-labeled CRN00808 as intravenous and oral forms.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]-CRN00808

Investigational drug

DRUG

CRN00808

Investigational drug

Sponsors & Collaborators

  • Crinetics Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-17
Primary Completion
2019-10-25
Completion
2019-10-25
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04246749 on ClinicalTrials.gov